Latest news

Dr Kosh Agarwal discusses results of the REEF-2 study at the International LIver Congress. Photo © Steve Forrest & Andrew McConnell / EASL.

Experimental hepatitis B combination suppresses key marker but fails to achieve functional cure.

People cured of hepatitis C remain at higher risk of death due to liver- and drug-related causes.

Short-course treatment prevents hepatitis C after organ transplant.

Bepirovirsen suppresses hepatitis B surface antigen, moves forward to larger functional cure studies

Keith Alcorn / 29 June 2022

Bepirovirsen, an experimental drug with a novel mode of action, suppressed hepatitis B surface antigen below the limits of detection in approximately 30% of patients after 24 weeks of treatment and ...
Bulevirtide leads to sustained improvement for people with hepatitis D

Liz Highleyman / 28 June 2022

The entry inhibitor bulevirtide (Hepcludex) led to a reduction in hepatitis delta virus (HDV) viral load, lower liver enzyme levels and improvement in fibrosis after 48 weeks of follow-up, according to findings ...